Top

17-07-2018 | Osteoporosis | Review | Article

Denosumab in the treatment of glucocorticoid-induced osteoporosis

Journal: Rheumatology International

Author: Ilke Coskun Benlidayi

Publisher: Springer Berlin Heidelberg

Abstract

Glucocorticoid therapy is the number one cause of secondary osteoporosis particularly effecting young individuals. Possessing an increased risk for fractures, glucocorticoid-induced osteoporosis might interfere with patients’ well-being and quality of life. Therefore, proper treatment of bone loss and prevention from fractures are of great importance. There are a limited number of therapeutic and preventative options for glucocorticoid-induced osteoporosis. Denosumab, with its high anti-resorptive potential, has been studied several times among patients on glucocorticoid therapy. However, a comprehensive look analysing the current data is lacking. Thus, the objective of the current article is to evaluate the current evidence on the efficacy, as well as the safety profile of denosumab in glucocorticoid-induced osteoporosis. Pubmed/MEDLINE, Scopus and Web of Science databases were searched for the terms denosumab, glucocorticoid-induced osteoporosis, steroid-induced osteoporosis, glucocorticoids and osteoporosis. Relevant data regarding the efficacy and safety of denosumab among patients with glucocorticoid-induced osteoporosis was analysed. Denosumab contributes to increased bone mineral density and decreased bone-turnover marker levels among glucocorticoid users. It is an effective therapeutic option with a favourable safety profile in glucocorticoid-induced osteoporosis.

Saag KG, Buttgereit F (2019) Systemic glucocorticoids in rheumatology. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 488–498

Curtis J, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420–426CrossRef

Hsu E, Nanes M (2017) Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 24:411–417CrossRef

Coskun Benlidayi I, Basaran S, Evlice A, Erdem M, Demirkiran M (2015) Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. Acta Clin Belg 70:188–192CrossRef

Pereira RM, Carvalho JF, Canalis E (2010) Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 65:1197–1205CrossRef

Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S et al (2017) Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo 69:30–39CrossRef

Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709–1718CrossRef

Kim D, Cho SK, Park B, Jang EJ, Bae SC, Sung YK (2018) Glucocorticoids are associated with an increased risk for vertebral fracture in patients with rheumatoid arthritis. J Rheumatol 45:612–620CrossRef

Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937–948PubMedPubMedCentral

10.

González-Macías J, Del Pino-Montes J, Olmos JM, Nogués X, en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM (2015) Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). Rev Clin Esp 215:515–526CrossRef

11.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 69:1521–1537CrossRef

12.

Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) et al (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Jt Bone Spine 81:493–501CrossRef

13.

Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Scientific Advisory Council of Osteoporosis Canada et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873CrossRef

14.

Chitre M, Shechter D, Grauer A (2011) Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm 68:1409–1418CrossRef

15.

Gu HF, Gu LJ, Wu Y, Zhao XH, Zhang Q, Xu ZR et al (2015) Efficacy and safety of denosumab in postmenopausal women with osteoporosis: a meta-analysis. Medicine (Baltimore) 94:e1674CrossRef

16.

United States Food and Drug Administration (2018) https://www.accessdata.fda.gov/drugsatfda_docs /label/2018/125320s186lbl.pdf. Accessed 3 Jul 2018

17.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef

18.

Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine. https://doi.org/10.1007/s12020-018-1588-2 CrossRefPubMedPubMedCentral

19.

Jacobs JWG, Bijlsma JWJ (2017) Glucocorticoid therapy. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’dell JR (eds) Kelley and Firestein’s textbook of rheumatology, 10th edn. Elsevier, Philedelphia, pp 932–957CrossRef

20.

Lau AN, Sambrook PN, Adachi JD (2015) Glucocorticoid-induced osteoporosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 6th edn. Elsevier, Philadelphia, pp 1674–1678

21.

Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121–132CrossRef

22.

Deal CL, Abelson AG (2019) Management of osteoporosis. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 1671–1682

23.

Kim K, Kim JH, Kim I, Lee J, Seong S, Park YW et al (2015) MicroRNA-26a regulates RANKL-induced osteoclast formation. Mol Cells 38:75–80PubMed

24.

Akbar MA, Nardo D, Chen MJ, Elshikha AS, Ahamed R, Elsayed EM et al (2017) Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions. Mol Med 21:23

25.

Scott LJ (2014) Denosumab: a review of its use in postmenopausal women with osteoporosis. Drugs Aging 31:555–576CrossRef

26.

Mok CC, Ho LY, Ma KM (2015) Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75:222–228CrossRef

27.

Matsuno H (2016) Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R D 16:347–353CrossRef

28.

Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T et al (2018) The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS One 13:e0193846CrossRef

29.

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454CrossRef

30.

Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28:1127–1137CrossRef

31.

Sawamura M, Komatsuda A, Togashi M, Wakui H, Takahashi N (2017) Effects of denosumab on bone metabolic markers and bone mineral density in patients treated with glucocorticoids. Intern Med 56:631–636CrossRef

32.

Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A (2017) The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos 12:44CrossRef

33.

Suzuki T, Nakamura Y, Kato H (2018) Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol 22:1–5

34.

Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Denosumab RA Study Group et al (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872–875CrossRef

35.

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523CrossRef

36.

Deeks ED (2018) Denosumab: a review in postmenopausal osteoporosis. Drugs Aging 35:163–173CrossRef

37.

Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835–2844CrossRef

38.

Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291–1299CrossRef

39.

Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54CrossRef

40.

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161CrossRef

41.

Fontalis A, Kenanidis E, Prousali E, Potoupnis M, Tsiridis E (2018) Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. Expert Opin Drug Saf 17:413–428CrossRef

42.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980CrossRef

43.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al FREEDOMTrial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRef

44.

Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479CrossRef

45.

Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D et al (2013) Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 42:27–40CrossRef

46.

Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRef

47.

Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773–2783CrossRef

48.

Miller PD (2011) A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 3:271–282CrossRef

49.

Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L et al (2016) Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant 16:1882–1891CrossRef

50.

Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B et al (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. https://doi.org/10.1007/s00198-018-4533-6 CrossRefPubMed

51.

Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, National Osteoporosis Guideline Group (NOGG) et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43CrossRef

52.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T (2017) Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 73:517–523CrossRef

53.

Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA (2016) Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 27:367–375CrossRef

54.

Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163–3170CrossRef

Medicine Matters Rheumatology

Abstract